SynthesisCombinatorial chemistry & high throughput screening2024
Association between Postmenopausal Osteoporosis and IL-6、TNF-α: A Systematic Review and A Meta-analysis.
Synthesis in Combinatorial chemistry & high throughput screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 13 citations in OpenAlex.
- Proteomics-Guided Computational Prioritization of Putative RANKL-Binding Peptides from Proteins Identified in Deer Horn Glue.International journal of molecular sciences · 2026Article
- Sex-Based Differences in the Vitamin D Metabolite Ratio and Its Associated Factors Among Healthy Japanese Adults: A Cross-Sectional Study.Biomedicines · 2026Article
- Anti-osteoporotic potential of Lawsonia inermis leaf extract: integration of network pharmacology, molecular docking, and experimental validation in ovariectomized rats.Inflammopharmacology · 2026Article
- The gut-bone axis: impact of diet on gut microbiome and osteoporosis.Bone research · 2026Review
- MSC-Derived Apoptotic Vesicles Restore Bone Marrow Niche Homeostasis in Postmenopausal Osteoporosis by miRNA-Mediated Suppression of MAPK and NF-κB Signaling Nodes.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- In Silico Investigation RevealsMedical sciences (Basel, Switzerland) · 2026Article
- The role of the gut-lung axis in persistent inflammation and disease progression in chronic obstructive pulmonary disease: mechanistic evidence and therapeutic implications.Frontiers in immunology · 2026Review
- Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer's disease.Frontiers in immunology · 2026Review
- A novel circulating osteoimmunological signature for diagnosis: integrating CXCL2, FYN, galectin-3, and STING in postmenopausal osteoporosis.Frontiers in physiology · 2026Article
- The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.Frontiers in immunology · 2026Review
- Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np).Journal of medical biochemistry · 2025Article
- Article
- TNF receptor-associated factors: promising targets of natural products for the treatment of osteoporosis.Frontiers in physiology · 2025Review
- A bibliometric analysis of the current state and future directions of osteoporosis pharmacological treatment.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostmenopausal osteoporosis (PMOP) greatly increases the risk of bone fracture in postmenopausal women, seriously affects the quality of life of patients, and is an important global public health problem. Persistent chronic systemic inflammation may be involved in the change process of PMOP, and many cytokines, such as TNF-alpha and Interleukin-6, play an important role in the inflammatory response. Therefore, This study takes commonly representative inflammatory factors as indicators to better determine their role in PMOP patients by means of databases from multiple studies for use in Meta-analysis. <p/> Method: Systematic review of studies on the relationship between PMOP and markers of inflammation: interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). Each effect size was expressed with a 95% confidence interval (CI), and I2 quantified the heterogeneity. The final results were aggregated and evaluated using random or fixed effects models. <p/> Results: Twenty-one original studies were identified. There were twenty studies involving IL-6 and eleven involving TNF-α. Overall, The levels of IL-6 [MD=23.93, 95% CI (19.65, 28.21)] and TNF-α [MD=2.9, 95% CI (2.37, 3.44)] were increased in PMOP patients compared with postmenopausal women without osteoporosis; The levels of IL-6 [MD=42.4, 95% CI (38.62, 46.19)] and TNF-α [MD=0.40, 95% CI (0.36, 0.44)] were significantly higher than those of premenopausal healthy women. <p/> Conclusions: The levels of inflammatory cytokines IL-6 and TNF-α were significantly increased in PMOP patients compared with controls, suggesting that persistent chronic inflammatory reaction exists in PMOP patients, which may be an important cause of aggravated osteoporosis in postmenopausal women. Therefore, the level of IL-6 and TNF-α indexes may be of great significance for the early prevention, diagnosis, treatment and prognosis assessment of PMOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.